Dayer P, Leemann T, Küpfer A, Kronbach T, Meyer U A
Eur J Clin Pharmacol. 1986;31(3):313-8. doi: 10.1007/BF00981130.
The influence of the debrisoquine/sparteine-type of oxidation polymorphism on plasma bufuralol concentration and the pattern of urine metabolites was studied in extensive and poor metabolizer subjects. (+)- and (-)-bufuralol, and (+)- and (-)-OH-bufuralol in plasma were determined by enantioselective HPLC, and urinary bufuralol and its metabolites were assayed by gas chromatography-mass spectrometry. Three hours after administration of racemic bufuralol the plasma (-)/(+) isomeric ratio for unchanged bufuralol was 1.84 in extensive metabolizers, indicating preferential clearance of the (+)-isomer through aliphatic 1'-hydroxylation and glucuroconjugation, while the (-)-isomer was mainly eliminated by aromatic 4-hydroxylation. Poor metabolizers were characterized by impaired 1'- and 4-hydroxylation, with almost total abolition of the stereoselectivity of these reactions. The data strongly suggest that both 1'- and 4-hydroxylation are catalyzed by the same enzyme. These in vivo observations are in agreement with recent in vitro data obtained in human liver microsomes from phenotyped patients and support the concept of deficiency of a highly stereoselective cytochrome P-450 isozyme as the cause of this polymorphism.
在快代谢型和慢代谢型受试者中研究了异喹胍/鹰爪豆碱型氧化多态性对血浆布呋洛尔浓度及尿液代谢产物模式的影响。采用对映体选择性高效液相色谱法测定血浆中的(+)-和(-)-布呋洛尔以及(+)-和(-)-羟基布呋洛尔,并用气相色谱-质谱法分析尿液中的布呋洛尔及其代谢产物。消旋布呋洛尔给药3小时后,快代谢型受试者中未变化的布呋洛尔的血浆(-)/(+)异构体比率为1.84,表明(+)-异构体通过脂肪族1'-羟基化作用和葡萄糖醛酸结合作用被优先清除,而(-)-异构体主要通过芳香族4-羟基化作用消除。慢代谢型受试者的特征为1'-和4-羟基化作用受损,这些反应的立体选择性几乎完全消失。数据强烈提示1'-和4-羟基化作用均由同一种酶催化。这些体内观察结果与最近从表型患者的人肝微粒体中获得的体外数据一致,并支持高度立体选择性细胞色素P-450同工酶缺乏是这种多态性原因的概念。